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Center, Stanford, CABackground: Chronic graft-versus-host disease (cGVHD)
remains a major barrier to successful use of HCT. The
incidence, clinical presentation, course, and outcomes of
GVHD-related syndromes are not well described in a
multi-center setting.
Methods: The Chronic GVHD Consortium enrolled allogeneic
HCT recipients in a prospective, longitudinal, observational
study, and followed them closely for development of four
GVHD-related syndromes: Late acute GVHD, cGVHD (both
deﬁned according to NIH consensus criteria), bronchiolitis
obliterans syndrome (BOS), and cutaneous sclerosis (CS).
Participants were enrolled up to 121 days after HCTas long as
they had not already developed a late immune-mediated
disorder. Research samples were drawn at day 100 and
again at day 180 or 365 post HCT. Subjects who developed
GVHD syndromes underwent additional sampling and data
collection.
Results: AllogeneicHCTrecipients (N¼913)wereenrolledat13
centers from March 2011 to May 2014. The cumulative inci-
dence of cGVHD was 51% with a median onset of 7.3 months
(Table), and86%ofcGVHDcaseswerediagnosedwithin theﬁrst
year after HCT. Late acute GVHD and BOS had particularly poor
survival with 29% and 36% non-relapse mortality (NRM) at 2
years after syndrome onset. In multivariable analysis, KPS <
80% at HCT (HR: 2.6, 95% CI:1.6-4.0, p<0.001) was associated
with a higher risk of late acute GVHD. Unrelated cord bloodTable
Syndrome Number
of cases
Cumulative incidence
at 2 years (95% CI)
Medi
mos
Late acute GVHD 85 11% (9%-14%) 5.2
Chronic GVHD 339 51% (47%-55%) 7.3
BOS 25 5% (3%-8%) 11.4
CS 44 10% (7%-13%) 13.5transplantation (UCBT) was associated with a lower risk of
cGVHD (HR 0.5, 95% CI 0.3-0.7, p<0.001). At 2 years after HCT
the probability of GVHD-free, relapse-free survival was 21%
(95% CI: 17%-24%) including only the late immune-mediated
disorders, and 9% (95% CI: 7%-12%) if classic acute GVHD was
included as an event.
Conclusions: This is the ﬁrst prospective study evaluating
incidence and outcomes of GVHD-related syndromes. The
onset of the syndromes varied from a median of 5.2 to 13.5
months after HCT, indicating need for continuous close
monitoring and management. Amongst the GVHD-related
syndromes, late acute GVHD and BOS have particularly
poor overall survival, indicating a need for more
effective treatments. Since research samples were banked,
further studies examining biologic correlates of these
syndromes are planned. Investigators interested in access
to data or samples should contact the Chronic GVHD
Consortium. (http://www.rarediseasesnetwork.org/cgvhd/
about/ OR chronicgvhdstudies@fhcrc.org).
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Background: Allo-LS is an important complication of HCT.
Early RV infection is assumed to be a predictor for allo-LS.
We routinely screen patients pre-HCT for RV, both in
Nasopharyngeal Aspirate (NPA) and BAL. This study
evaluates the impact of RV RNA-DNA-positivity pre-HCT
from NPA or BAL respectively on the occurrence of allo-LS.
Methods: We prospectively included all consecutive pedi-
atric HCT recipients from January 2007eOctober 2013. A PCR
on a panel of RV (Adenovirus, Coronavirus, Rhinovirus, RSV,
Bocavirus, Inﬂuenzavirus A and B, Parainﬂuenza 1-3 and 2-4,
human-Metapneumovirus) was performed on BAL and NPA
samples a week prior to HCT. Primary endpoint was allo-LS,
deﬁned according to international criteria as Idiopathic
Pneumonia Syndrome (acute respiratory symptoms,
pulmonary inﬁltrates, absence of infection) or Bronchiolitis
Obliterans (HRCT changes such as air trapping and ground
glass, abnormal obstructive pulmonary function test,
absence of infection). Cox proportional hazard models were
used for analyses.an time to onset,
(range)
NRM 2 years after
onset (95% CI)
Survival 2 years
after onset (95% CI)
(3.2-15.6) 29% (15%-54%) 57% (33%-76%)
(1.8-22.0) 17% (11%-26%) 77% (67%-84%)
(2.8-21.7) 36% (15%-90%) 62% (22%-86%)
(4.0-26.5) 12% (4%-36%) 88% (65%-96%)
Figure 1. Cumulative incidence of allo-LS for BAL-RV positive, NPA-RV positive
and RV negative patients
Figure 2. Cumulative incidence of allo-LS for Rhinovirus positive,
non-Rhinovirus positive and RV negative patients.
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(0.6-22.7), transplanted for leukemia/lymphoma (51%), bone
marrow failure syndromes (9%), primary immune deﬁciency
(PID) (18%) and non-PID benign disorders (22%). Myelo-
ablative conditioning regimen was used; chemotherapy
based in 85%, containing Total Body Irradiation in 15%. Do-
nors used: Matched family (26%), unrelated cord blood (54%)
and unrelated bone marrow (20%). In 57% of patients pre-
HCT NPA was positive for RV. RV was detected in 40% of BAL
samples. In 37% of NPA-RV positive patients BAL was nega-
tive, whereas only 7% of BAL positives were NPA negative.
Rhinovirus was the most frequently detected virus (43%).There was a similar distribution of the various viruses in
BAL and NPA. Most patients had no or very mild signs
of upper respiratory tract infection at time of sampling.
In multivariate analyses BAL RV positivity was the
only predictor associated with allo-LS: HR 3.89, 95% CI
1.41e10.40; p¼0.009). NPA-only positivity was not
associated with allo-LS (Fig. 1). No signiﬁcant difference was
found between Rhino- and nonRhino virus in the risk for
allo-LS (Fig. 2).
Conclusion: RV positivity is frequently seen in pediatric
patients pre-HCT. Rhinovirus was the most commonly found
RV. RV positivity in BAL pre-HCT is a strong predictor for
allo-LS in children post-HCT. This association was similar for
Rhino- and nonRhinovirus positive patients. These data
support the importance of identifying patients at risk for
allo-LS by pre-HCT BAL. Early recognition may guide
preventive strategies: e.g. postponement of elective HCTs
and delayed tapering of immune-suppression.38
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We previously showed that adoptive transfer of 3 million
Treg per kilogram recipient body weight could reduce the
risk of acute GVHD (aGVHD) (39% vs. 61%, p-0.05; Blood
117:1061) in recipients of double UCBT. We hypothesized
that control of GVHD was suboptimal, likely related to the
low ratio of Treg to T cells in the UCB graft (i.e., 0.3:1.0). Our
group previously demonstrated optimal murine GVHD con-
trol with Treg:Teffector ratio  1:1. A genetically modiﬁed
K562 cell line, termed KT64/86, that expressed CD64, a high
afﬁnity Fc receptor loaded with anti-CD3 antibody, and
CD86, the natural ligand of CD28/CTLA-4, was used to
manufacture higher doses of Treg from a single UCB unit, that
retained the CD4+CD25+FoxP3+ CD127- phenotype and
had potent in vitro and in vivo (murine xenogeneic) sup-
pression of T cell proliferation. Using this methodology, we
performed a phase I dose escalation trial starting with 3
million donor Treg/kg. Patients who were candidates for
nonmyeloablative double UCBT were eligible. Ten patients
received Cy50/FLU200/TBI200 nonmyeloablative condition-
ing with sirolimus and mycophenolate mofetil immuno-
suppression. Thawed Tregs underwent a single CD25 positive
selection and were cultured for 181 days in the presence of
KT64/86 (1:1) supplemented with 300 units/mL rhIL-2;
cultures were restimulated with KT64/86 on day 12. In the
dose escalation, 3 to 100 million Tregs/kg were infused on
day +1 and patients monitored for infusional toxicity and
GVHD. Fifteen concurrent patients received same treatment
regimen but no Treg served as controls for clinical endpoints.
